More accurate, less costly diagnostic for peripheral artery disease studied.

According to researchers from cardiac disease diagnostic maker Prevencio, recent data shows a new blood test may offer physicians a diagnostic option to detect peripheral artery disease (PAD). The findings, presented recently at American Heart Association’s 2017 Scientific Sessions, demonstrated the accuracy of the company’s multi-protein blood test, HART™ PAD, that in development, employed clinical data analytics and machine learning to power its ability to identify PAD in the bloodstream.

Prevencio explained the diagnostic is designed to detect PAD accurately and help predict the need for future medical interventions. According to Prevencio, PAD is a circulatory problem where plaque-narrowed arteries constrict blood flow to a patient’s organs (kidneys) and extremities. If left untreated, PAD can lead to an increased risk of life-threatening complications associated with major cardiac events, trauma and amputation.

In the study, Prevencio and Massachusetts General Hospital’s Principal Investigator James L. Januzzi, MD and a team of researchers, developed and validated the multi-protein blood test that detects PAD accurately. Affecting more than 202 million people globally, Prevencio said the condition is underdiagnosed and as a result goes undertreated--until the disease has reached its advanced stages.

Januzzi explained: “This blood test may allow for the diagnosis and treatment of many more patients with PAD, and in addition to the opportunity for more appropriate care of patients, we believe it could benefit more cardiac clinical trials, by saving time and thereby lowering overall trial costs.”

Rhonda Rhyne, Prevencio’s CEO added: “We are pleased to work with Massachusetts General Hospital, Dr. Januzzi and his researchers … to develop novel and highly accurate blood tests to improve diagnosis and treatment for millions of cardiovascular patients. It is also highly rewarding to work with pharmaceutical companies to improve drug development and decrease clinical trial expenses.”